Stockscreener 앱 받기
28.97
1.94%
0.55
전일 마감가:
$28.42
열려 있는:
$28.25
하루 거래량:
296.36K
Relative Volume:
3.10
시가총액:
$320.23M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.54%
1개월 성능:
+36.39%
6개월 성능:
+119.80%
1년 성능:
+0.00%
1일 변동 폭
$28.19
$29.50
1주일 범위
$25.80
$29.50
52주 변동 폭
$11.17
$29.50
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
125 STRAFFORD AVE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
28.96 | 285.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.01 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.88 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.26 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser
Why Palvella Therapeutics Inc. stock attracts strong analyst attentionLow Risk Entry Points - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Yahoo Finance
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener
Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 2500 Growth Index - MarketScreener
Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener
Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph
Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN
Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World
Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks
Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World
Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa
Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com
Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com
Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune
Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan
Brokers Set Expectations for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MyChesCo
Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria
Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.69%
2.49%
자본화:
|
볼륨(24시간):